1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
107 citations
,
December 2003 in “Dermatologic Therapy” Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
1 citations
,
December 2016 JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
April 2019 in “Journal of Investigative Dermatology” Blocking LFA-1 prevents hair loss in mice.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
31 citations
,
February 2014 in “Inflammation Research” Lower CD200R1 on certain immune cells is linked to more severe rheumatoid arthritis and immune imbalance.
18 citations
,
February 2022 in “Cell Death Discovery” ECM1-modified stem cells can effectively treat liver cirrhosis.
January 2025 in “Cell Communication and Signaling” CXXC5 can both suppress and promote cancer, making it a complex target for treatment.
April 2017 in “Journal of Investigative Dermatology” HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.
August 2019 in “International journal of dermatology and venereology” The calcineurin/NFAT pathway plays a significant role in the development and growth of a type of skin cancer called cutaneous squamous cell carcinoma.
March 2018 in “Suez Canal University Medical Journal” New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
32 citations
,
February 2024 in “The Journal of Experimental Medicine” CXCL12+ fibroblasts help recruit neutrophils to fight skin infections.
10 citations
,
September 2021 in “The FASEB Journal” ACKR2 helps prevent skin scarring and hair loss by controlling inflammation.
2 citations
,
July 2022 in “The Kaohsiung Journal of Medical Sciences” FTY720 helps transplanted fat survive better by reducing immune rejection and improving blood vessel growth.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Folliculotropic mycosis fungoides has unique molecular features and cell interactions that could guide targeted therapy.
March 2026 in “Wound Repair and Regeneration” MARCKSL1 is important for wound healing and could be a target to reduce scarring.
26 citations
,
June 2024 in “Frontiers in Immunology” SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.
1 citations
,
December 2023 in “Nanomaterials” Combining specific nanoparticles with immune therapy significantly improves cancer treatment.
4 citations
,
August 2023 in “Biomedicine & Pharmacotherapy” Ivacaftor can protect against noise-induced hearing loss by reducing oxidative stress.
January 2011 in “Junshi yixue” A mouse model for studying scleroderma in chronic graft-versus-host disease was successfully created.
57 citations
,
June 2003 in “American Journal of Physiology-cell Physiology” Cyclosporin A helps mice grow hair by blocking a specific protein activity in skin cells.
1 citations
,
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Higher levels of certain proteins may increase or decrease rosacea risk.
25 citations
,
January 2019 in “Annals of Dermatology” Blocking the NOTCH pathway can prevent fibrosis in systemic sclerosis.
16 citations
,
March 2017 in “Oncotarget” SOCS3 treatment can prevent hair loss by stopping harmful immune responses.
November 2025 in “Cancer Cell International” Cancer-associated fibroblasts promote tumor growth in skin cancer.
April 2026 in “Dermatology and Therapy” TNFα inhibitors are effective and well-tolerated for treating severe scalp cellulitis.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
4 citations
,
January 2021 in “Journal of Clinical Medical Research” c-Kit is important for heart regeneration and cancer development.
Infliximab was effective in treating a scalp condition that did not respond to other treatments.